Trials / Completed
CompletedNCT00395863
Multihance at 3 Tesla (3T) in Brain Tumors
A Phase IV Double-blind Multicenter Randomized Crossover Study to Compare 0.10 mmol/kg of Multihance With 0.10 mmol.kg of Magnevist in Magnetic Resonance Imaging(MRI) of the Brain at 3T
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Bracco Diagnostics, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Compare the efficacy of MultiHance and Magnevist
Detailed description
The purpose of this study was to evaluate whether Multihance is superior to Magnevist in terms of qualitative and quantitative assessment of unenhanced MRI and contrast-enhanced MRI for the visualization of brain disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Multihance | 0.5 M at a single injection |
| DRUG | Arm 2 - Magnevist | 0.5 M Magnevist at a single dose injection |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2008-02-01
- Completion
- 2008-03-01
- First posted
- 2006-11-06
- Last updated
- 2020-11-05
- Results posted
- 2009-07-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00395863. Inclusion in this directory is not an endorsement.